David Altshuler - Feb 24, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role: EVP, Global Research and CSO
Signature: /s/ Joy Liu, Attorney-in-Fact
Stock symbol: VRTX
Transactions as of: Feb 24, 2023
Transactions value $: -$2,366,256
Form type: 4
Date filed: 2/28/2023, 03:40 PM
Previous filing: Feb 22, 2023
Next filing: Aug 11, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRTX	Common Stock	Tax liability	-$1.15M	-3.97K	-9.86%	$289.12	36.3K	Feb 24, 2023	Direct
transaction	VRTX	Common Stock	Sale	-$1.04M	-3.64K	-10.02%	$287.23	32.6K	Feb 27, 2023	Direct	F1, F2, F3
transaction	VRTX	Common Stock	Sale	-$86.6K	-300	-0.92%	$288.74	32.3K	Feb 27, 2023	Direct	F1, F2, F4
transaction	VRTX	Common Stock	Sale	-$87.5K	-302	-0.93%	$289.60	32K	Feb 27, 2023	Direct	F1, F2, F5

Showing 1 to 4 of 4 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2	Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3	Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72).
F4	Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37).
F5	Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65).